美国《生物安全法案》风波仍持续在市场中发酵。日前,据媒体报道,美国立法者正在积极考虑对《生物安全法案》进行修订,以期达成一个更具妥协性的版本。这一新版本的核心在于引入对相关公司的行政审查环节,而非直接禁止生物制药公司与中国公司的合作。市场对这一消息反应积极,CXO板块震荡走强。12月6日,截至收盘,药明康德涨至7.41%,博腾股份涨超10%,成都先导、康龙化成、昭衍新药、凯莱英等涨幅居前。美国《...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.